Duvyzat (Givinostat Hydrochloride) Patent Expiration, LOE Window & CMS Spending

Duvyzat (Givinostat Hydrochloride) by Italfarmaco Spa: FDA Orange Book core substance LOE 2040-05-03, 0 AB generics, $25.2M 2024 CMS Part D & Medicaid spend, and $37,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorItalfarmaco Spa
FDA Application & PathwayN217865 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-05-03
Last Listed Patent or Exclusivity Date2040-05-03
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$25.2M
2024 Medicare Part D Spend$2.0M
2024 Medicaid Spend$23.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($37,000 intro WAC)